Clinical Trials
85 trialsNCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT02372409 2024-11-01
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02096588 2024-07-09
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00060346 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
NCT02833766 2021-09-29
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Swiss Cancer Institute
Phase 2 Terminated
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00542191 2021-05-26
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Leo W. Jenkins Cancer Center
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT02758366 2021-02-09
Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
Meyer Children's Hospital IRCCS
Phase 2 Terminated
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT03698227 2020-07-15
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00038142 2020-01-29
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00574236 2019-12-13
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT02472353 2019-10-16
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
Avera McKennan Hospital & University Health Center
Phase 2 Terminated
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT00484601 2019-02-11
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02255110 2018-12-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
Phase 2 Terminated
NCT02560051 2018-11-28
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02494713 2018-11-27
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00080782 2018-10-31
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00809341 2018-09-25
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00804830 2018-08-28
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
Phase 2 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT02419469 2018-06-11
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00089544 2018-04-13
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01313884 2017-11-24
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Stanford University
Phase 2 Terminated